StockNews.com initiated coverage on shares of Blueprint Medicines (NASDAQ:BPMC – Get Rating) in a report issued on Thursday. The firm issued a hold rating on the biotechnology company’s stock. Several other equities research analysts have also commented on BPMC. VNET Group reiterated a maintains rating on shares of Blueprint Medicines in a research report on […]